Vancomycin
Also known as: Firvanq, Lyphocin, VAN, Vancocin, Vancocin HCl, Vancoled, Vancomycin hydrochloride
Source Vancomycin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Vancomycin is a prescription‑only glycopeptide antibiotic used primarily for serious infections caused by Gram‑positive bacteria, including Clostridioides difficile colitis and methicillin‑resistant Staphylococcus aureus (MRSA) pneumonia. It is administered intravenously, orally, or intrathecally, depending on the infection site. Clinical trials show it achieves cure rates around 60 %–90 % for C. difficile infection, while meta‑analyses indicate comparable mortality to linezolid for MRSA pneumonia but lower clinical cure rates. Resistance, especially vancomycin‑resistant enterococci, is increasing worldwide.
Mechanism of Action
Inhibits bacterial cell wall synthesis by binding to the D-Ala-D-Ala terminus of peptidoglycan precursors, preventing transglycosylation and transpeptidation, leading to cell lysis and death.
What the Research Shows
Evidence from recent literature includes a 2024 meta‑analysis showing rising vancomycin resistance among Enterococcus faecalis worldwide, with notable geographic variation. A 2025 randomized trial compared oral vancomycin (125 mg qid for 10 days) to fecal microbiota transplantation for primary C. difficile infection, finding non‑inferior cure rates (61.2 % vs 66.7 %). An earlier 2011 phase‑3 trial demonstrated similar initial cure to fidaxomicin but higher recurrence (25.3 % vs 15.4 %). A 2021 meta‑analysis of MRSA pneumonia trials found vancomycin mortality comparable to linezolid, though linezolid achieved higher clinical cure. A 2022 systematic review identified multiple patient‑ and drug‑related risk factors for vancomycin‑associated acute kidney injury, including high trough levels and concomitant nephrotoxins. Finally, a 2023 review highlighted higher mortality associated with vancomycin‑resistant enterococcal bloodstream infections.
Reported Benefits
Clinical data support vancomycin as an effective option for treating C. difficile infection, achieving cure in about two‑thirds of patients and comparable mortality to linezolid in MRSA pneumonia. Its oral formulation allows direct delivery to the gut for colitis, while intravenous use treats systemic Gram‑positive infections. The drug remains a cornerstone therapy where resistance is low, such as in parts of Europe and Australia.
Limitations of the Evidence
Increasing resistance, especially among Enterococcus spp., limits efficacy in some regions. In C. difficile infection, vancomycin is associated with higher recurrence rates than fidaxomicin and does not outperform fecal microbiota transplantation in recent trials. For MRSA pneumonia, linezolid shows superior clinical cure. The need for therapeutic drug monitoring and the risk of nephrotoxicity further constrain its use.
Safety Considerations
Vancomycin can cause acute kidney injury, with risk rising when trough concentrations exceed 15 µg/mL, treatment exceeds 14 days, or nephrotoxic agents (e.g., amphotericin B, acyclovir, piperacillin‑tazobactam) are co‑administered. Patients with pre‑existing renal disease, obesity, or critical illness are also at higher risk. Reported adverse events in comparative trials were similar to control agents, but careful monitoring of renal function and drug levels is advised.
How It Is Administered
Vancomycin is available for intravenous, oral, and intrathecal administration. Oral dosing for C. difficile infection is typically 125 mg four times daily for 10 days. Intravenous regimens vary by infection severity and require serum trough monitoring. Intrathecal use is reserved for central nervous system infections when other options are unsuitable.
Routes of Administration
Goals & Uses
- Treatment of enterococcal infectionsAntimicrobial TherapyHigh
- Surgical prophylaxis in beta-lactam allergic patientsProphylaxisModerate
- Treatment of C. difficile colitisInfectionHigh
- Treatment of MRSA infectionsAntimicrobialHigh
- Prophylaxis in neutropenic patientsPreventionModerate
- Treatment of Clostridioides difficile colitisAntimicrobial TherapyHigh
- Treatment of CNS infections (meningitis)Antimicrobial TherapyModerate
Contraindications
- Severe pre-existing hearing lossOtotoxicity RiskModerate
- Known hypersensitivity to vancomycinAllergyHigh
- Hypersensitivity to vancomycinAllergyHigh
- Severe renal impairment with no dose adjustmentRenalModerate
- Vancomycin-resistant organisms (VRE)Microbial ResistanceHigh
Adverse Effects
- ThrombophlebitisVascularCommon
- ThrombocytopeniaHematologicRareLow platelet count
- OtotoxicityAuditory/vestibularUncommon
- HypotensionCardiovascularUncommonLow blood pressure
- Red‑man syndromeInfusion‑relatedCommon
- Red man syndromeInfusion ReactionCommon
- NeutropeniaHematologicUncommonLow neutrophil count
- NephrotoxicityRenalCommon
Drug Interactions
- AminoglycosidesHigh
- Neuromuscular blocking agentsModerate
- Aminoglycosides (e.g., gentamicin, tobramycin)High
- Piperacillin-tazobactamModerate
- NSAIDsModerateMay increase renal risk in susceptible patients
- NSAIDs (e.g., indomethacin)Moderate
- Loop diuretics (e.g., furosemide)Moderate
Population Constraints
- Pregnancy (Category C/B2)PregnancyRelative
- Renal impairmentOrgan ImpairmentRelative
- ElderlyAgeRelative
- Elderly patientsAgeRelative
- Neonates and premature infantsPediatricRelative
- Pregnant womenReproductiveRelative
- NeonatesPediatricRelative
- Hearing-impaired patientsPre Existing ConditionRelative
Regulatory Status
- European UnionApprovedApproved: Serious Gram‑positive infections, C. difficile colitis (oral)Similar to US
- United StatesApprovedApproved: Complicated skin and skin‑structure infections, Bacteremia, Endocarditis, Osteomyelitis, C. difficile colitis (oral)IV and oral formulations
- United KingdomApprovedApproved: Severe Gram‑positive infections, C. difficile colitis
Therapeutic drug monitoring recommended for IV use; monitor renal function and hearing; red‑man syndrome can occur with rapid infusion.
Evidence & Sources
- Journal ArticleHighGuan L, et al.2024-01-01T00:00:00.000000Z
- Journal ArticleModerateJuul FE, et al.2025-01-01T00:00:00.000000Z
- Journal ArticleModerateLouie TJ, et al.2011-01-01T00:00:00.000000Z
- Journal ArticleHighKato H, et al.2021-01-01T00:00:00.000000Z
- Journal ArticleHighKim JY, et al.2022-01-01T00:00:00.000000Z
- Journal ArticleHighEichel VM, et al.2023-01-01T00:00:00.000000Z
Frequently Asked Questions
When is oral vancomycin preferred over other treatments for C. difficile infection?
Oral vancomycin is used as a first‑line option for primary C. difficile infection, achieving cure in about 60 % of patients. Recent trials show it is non‑inferior to fecal microbiota transplantation, though newer agents like fidaxomicin may lower recurrence rates.
How does vancomycin compare to linezolid for MRSA pneumonia?
Meta‑analyses indicate that mortality is similar between vancomycin and linezolid, but linezolid provides higher clinical cure and microbiological eradication rates. Choice may depend on drug tolerance, renal function, and local resistance patterns.
What are the main risk factors for vancomycin‑associated kidney injury?
Higher trough levels (>15 µg/mL), prolonged therapy (>14 days), pre‑existing renal disease, obesity, intensive‑care admission, and concurrent nephrotoxic drugs (especially amphotericin B, acyclovir, piperacillin‑tazobactam) increase the odds of acute kidney injury.
Is vancomycin effective against vancomycin‑resistant enterococci?
By definition, vancomycin does not treat infections caused by vancomycin‑resistant enterococci (VRE). Studies show VRE infections are associated with higher mortality, underscoring the need for alternative agents in resistant cases.
What monitoring is required during intravenous vancomycin therapy?
Therapeutic drug monitoring of serum trough concentrations is recommended to keep levels ≤15 µg/mL when possible, reducing nephrotoxicity risk. Renal function should be assessed regularly, especially in patients receiving other nephrotoxic medications.
What is Vancomycin?
Vancomycin is a prescription‑only glycopeptide antibiotic used primarily for serious infections caused by Gram‑positive bacteria, including Clostridioides difficile colitis and methicillin‑resistant Staphylococcus aureus (MRSA) pneumonia. It is administered intravenously, orally, or intrathecally, depending on the infection site. Clinical trials show it achieves cure rates around 60 %–90 % for C. difficile infection, while meta‑analyses indicate comparable mortality to linezolid for MRSA pneumonia but lower clinical cure rates. Resistance, especially vancomycin‑resistant enterococci, is increasing worldwide.
What is Vancomycin used for?
Vancomycin is educationally associated with: Treatment of enterococcal infections, Surgical prophylaxis in beta-lactam allergic patients, Treatment of C. difficile colitis, Treatment of MRSA infections, Prophylaxis in neutropenic patients, Treatment of Clostridioides difficile colitis, Treatment of CNS infections (meningitis). Educational only — not medical advice.
How is Vancomycin administered?
Recorded routes of administration: Intrathecal, Intravenous, Oral, Topical.
What are the potential side effects of Vancomycin?
Reported adverse effects include: Thrombophlebitis, Thrombocytopenia, Ototoxicity, Hypotension, Red‑man syndrome, Red man syndrome, Neutropenia, Nephrotoxicity. This list is not exhaustive — consult a qualified clinician.
Who should avoid Vancomycin?
Recorded contraindications: Severe pre-existing hearing loss, Known hypersensitivity to vancomycin, Hypersensitivity to vancomycin, Severe renal impairment with no dose adjustment, Vancomycin-resistant organisms (VRE). Consult a qualified clinician before use.